Could this Healthcare Stock really climb 1,802.65% in 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Gold Could Be Heading for Record Highs - But How to Play It?]( [See this little-known way to play in the rising gold market.]( --------------------------------------------------------------- March 7, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Is This The Most Overlooked Gold Investment Strategy of 2024?]( is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks. [Read this stunning report on a little-known gold royalty investment strategy]( --------------------------------------------------------------- [Cingulate Inc.]( Symbol: [CING]( Recent Price: $1.13 Average Analyst Price Target: $21.50 (1,802.65%) Market Cap: $4.49M Last Year's EPS: $-11.4 Consensus EPS Forecast: $-4.8 Expected Earnings Date: Mar 08, 2024 Recent Analyst Action: Boobalan Pachaiyappan, analyst at H.C. Wainwright, reiterates coverage on [Cingulate Inc. (CING)]( in the Healthcare sector with a Buy rating and a price target of $8 (2 months ago). [TipRanks.com]( also reports that [Cingulate Inc.]( currently has 2 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $21.50 . The target pricing ranges from a high forecast of $8 down to a low forecast of $35. [Cingulate Inc. (CING)](’s last closing price was $1.13 which would put the average price target at 1,802.65% upside. Here are 3rd party ratings for [CING](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 29% (74 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Digital Dollar: Convenience or Control?]( the truth behind the digital dollar. Is it a step towards financial innovation or a leap into surveillance and control? See how you can protect yourself and your money with our free guide. [Protect Your Money ASAP]( --------------------------------------------------------------- [Algonquin Power & Utilities Corp.]( Symbol: [AQN]( Recent Price: $5.98 Average Analyst Price Target: $6.80 (13.78%) Market Cap: $4.12B Last Year's EPS: $0.08 Consensus EPS Forecast: $0.11 Expected Earnings Date: Mar 08, 2024 Recent Analyst Action: Nelson Ng, analyst at RBC Capital, reiterates coverage on [Algonquin Power & Utilities Corp. (AQN)]( in the Utilities sector with a Hold rating and a price target of $7 (1 month ago). [TipRanks.com]( also reports that [Algonquin Power & Utilities Corp.]( currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $6.80 . The target pricing ranges from a high forecast of $8 down to a low forecast of $5.52. [Algonquin Power & Utilities Corp. (AQN)](’s last closing price was $5.98 which would put the average price target at 13.78% upside. Here are 3rd party ratings for [AQN](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Bottom 33% (169 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( --------------------------------------------------------------- [Target Hospitality Corp.]( Symbol: [TH]( Recent Price: $8.59 Average Analyst Price Target: $15.50 (80.44%) Market Cap: $873.27M Last Year's EPS: $0.44 Consensus EPS Forecast: $0.43 Expected Earnings Date: Mar 08, 2024 Recent Analyst Action: Stephen Gengaro, analyst at Stifel Nicolaus, reiterates coverage on [Target Hospitality Corp. (TH)]( in the Industrials sector with a Buy rating and a price target of $14 (2 months ago). [TipRanks.com]( also reports that [Target Hospitality Corp.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $15.50 . The target pricing ranges from a high forecast of $20 down to a low forecast of $12. [Target Hospitality Corp. (TH)](’s last closing price was $8.59 which would put the average price target at 80.44% upside. Here are 3rd party ratings for [TH](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 45% (138 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Genesco Inc.]( Symbol: [GCO]( Recent Price: $28.62 Average Analyst Price Target: $31.00 (8.32%) Market Cap: $328.82M Last Year's EPS: $-0.85 Consensus EPS Forecast: $0.84 Expected Earnings Date: Mar 08, 2024 Recent Analyst Action: Jeff Lick, analyst at B.Riley Financial, reiterates coverage on [Genesco Inc. (GCO)]( in the Consumer Cyclical sector with a Hold rating and a price target of $31 (1 day ago). [TipRanks.com]( also reports that [Genesco Inc.]( currently has 1 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $31.00 . The target pricing ranges from a high forecast of $31 down to a low forecast of $31. [Genesco Inc. (GCO)](’s last closing price was $28.62 which would put the average price target at 8.32% upside. Here are 3rd party ratings for [GCO](: - TipRanks.com: Hold - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: hold - Zacks.com: Strong Sell, Bottom 34% (166 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [Anixa Biosciences, Inc.]( Symbol: [ANIX]( Recent Price: $3.50 Average Analyst Price Target: $10.50 (200.00%) Market Cap: $110.99M Last Year's EPS: $-0.08 Consensus EPS Forecast: $-0.09 Expected Earnings Date: Mar 08, 2024 Recent Analyst Action: Yi Chen, analyst at H.C. Wainwright, reiterates coverage on [Anixa Biosciences, Inc. (ANIX)]( in the Healthcare sector with a Buy rating and a price target of $12 (3 weeks ago). [TipRanks.com]( also reports that [Anixa Biosciences, Inc.]( currently has 2 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $10.50 . The target pricing ranges from a high forecast of $9 down to a low forecast of $12. [Anixa Biosciences, Inc. (ANIX)](’s last closing price was $3.50 which would put the average price target at 200.00% upside. Here are 3rd party ratings for [ANIX](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 29% (74 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Revolutionary Device Redefines Cancer Detection]( the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time. [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketInsidersPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software